Theranostic Biomarkers of Non-Small Cell Bronchial Cancers

Thoracic oncology has benefited from therapeutic innovations based on better knowledge of cancer biology and the description of theranostic biomarkers for the use of oncogenic protein kinase inhibitors or immune checkpoints (CTLA 4 and PD L 1). The use of these drugs leads to the development of secondary resistance, some of which is accessible to specific therapies.
The GRC Théranoscan project is to participate in the research of theranostic biomarkers. This project is made possible by monitoring a large number of patients benefiting from these molecules in the standard of care practice and during therapeutic trials and the possibility of following them, by performing tissue or liquid biopsies to identify the mechanisms of resistance.
This expertise makes it possible to develop collaborative research programs, to supervise student researchers and to publish original works in this field.